NasdaqGS - Delayed Quote USD

Agios Pharmaceuticals, Inc. (AGIO)

33.00

+0.08

(+0.24%)

At close: May 10 at 4:00 PM EDT

33.00

0.00

(0.00%)

After hours: May 10 at 4:01 PM EDT

Key Events

Loading Chart for AGIO

9/21 12:03 PM

DELL

Previous Close 32.92
Open 32.94
Bid 32.99 x 100
Ask 33.04 x 100
Day's Range 32.45 - 33.09
52 Week Range 19.80 - 35.50
Volume 506,066
Avg. Volume 776,774
Market Cap (intraday) 1.874B
Beta (5Y Monthly) 0.81
PE Ratio (TTM) --
EPS (TTM) -6.31
Earnings Date Aug 1, 2024 - Aug 5, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 44.00

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

383

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AGIO

48.18%

S&P 500

9.49%

1-Year Return

AGIO

29.92%

S&P 500

26.79%

3-Year Return

AGIO

40.85%

S&P 500

23.39%

5-Year Return

AGIO

35.43%

S&P 500

81.93%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Agios Pharmaceuticals, Inc.

33.00

+0.24%

Mkt Cap 1.874B

Industry Biotechnology

PTC Therapeutics, Inc.

32.25

+3.86%

Mkt Cap 2.473B

Industry Biotechnology

Ultragenyx Pharmaceutical Inc.

40.90

-0.78%

Mkt Cap 3.4B

Industry Biotechnology

SpringWorks Therapeutics, Inc.

40.89

-4.80%

Mkt Cap 3.029B

Industry Biotechnology

65.48

-3.02%

Mkt Cap 4.227B

Industry Biotechnology

22.48

-4.50%

Mkt Cap 1.386B

Industry Biotechnology

Nurix Therapeutics, Inc.

13.51

-3.15%

Mkt Cap 825.022M

Industry Biotechnology

Protagonist Therapeutics, Inc.

28.23

-0.14%

Mkt Cap 1.656B

Industry Biotechnology

Alnylam Pharmaceuticals, Inc.

150.47

-0.59%

Mkt Cap 19.033B

Industry Biotechnology

Amicus Therapeutics, Inc.

9.23

-2.64%

Mkt Cap 2.734B

Industry Biotechnology

Ionis Pharmaceuticals, Inc.

39.08

-0.99%

Mkt Cap 5.704B

Industry Biotechnology

Valuation Measures

As of 5/10/2024

Market Cap

1.87B
Enterprise Value

1.34B
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

62.77
Price/Book (mrq)

2.52
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-24.55%
Return on Equity (ttm)

-39.61%
Revenue (ttm)

29.4M
Net Income Avi to Common (ttm)

-352.62M
Diluted EPS (ttm)

-6.31

Balance Sheet and Cash Flow

Total Cash (mrq)

597.99M
Total Debt/Equity (mrq)

9.19%
Levered Free Cash Flow (ttm)

-221.81M

AGIO does not have Company Insights

PTCT PTC Therapeutics, Inc.

32.25

+3.86%

RARE Ultragenyx Pharmaceutical Inc.

40.90

-0.78%

BPMC Blueprint Medicines Corporation

106.70

-1.51%

BLUE bluebird bio, Inc.

1.0600

-5.36%

ALNY Alnylam Pharmaceuticals, Inc.

150.47

-0.59%

PBYI Puma Biotechnology, Inc.

4.8100

+0.42%

SAGE Sage Therapeutics, Inc.

11.90

-3.57%

FOLD Amicus Therapeutics, Inc.

9.23

-2.64%

ENTA Enanta Pharmaceuticals, Inc.

12.65

-2.17%

MGNX MacroGenics, Inc.

3.3100

-77.44%

IONS Ionis Pharmaceuticals, Inc.

39.08

-0.99%

ESPR Esperion Therapeutics, Inc.

2.1900

+4.78%

PRTA Prothena Corporation plc

21.34

-3.00%

KPTI Karyopharm Therapeutics Inc.

1.0900

+1.87%

HALO Halozyme Therapeutics, Inc.

43.15

-1.57%

FGEN FibroGen, Inc.

1.1600

-4.92%